Cargando…
A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we id...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875126/ https://www.ncbi.nlm.nih.gov/pubmed/33585490 http://dx.doi.org/10.3389/fcell.2021.634697 |
_version_ | 1783649725212262400 |
---|---|
author | Song, Congkuan Wu, Zhiquan Wang, Qingwen Wang, Yujin Guo, Zixin Li, Sheng Hu, Weidong |
author_facet | Song, Congkuan Wu, Zhiquan Wang, Qingwen Wang, Yujin Guo, Zixin Li, Sheng Hu, Weidong |
author_sort | Song, Congkuan |
collection | PubMed |
description | Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we identified two genes (ANLN and ARNTL2) from multiple gene expression data sets, and developed a two-mRNA-based signature that can effectively distinguish high- and low-risk patients and predict patients’ response to immunotherapy. Furthermore, taking full advantage of the complementary value of clinical and molecular features, we combined the immune prognostic signature with clinical features to construct and validate a nomogram that can predict the probability of high tumor mutational burden (>10 mutations per megabyte). This may improve the estimation of immunotherapy response in LUAD patients, and provide a new perspective for clinical screening of immunotherapy beneficiaries. |
format | Online Article Text |
id | pubmed-7875126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78751262021-02-11 A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma Song, Congkuan Wu, Zhiquan Wang, Qingwen Wang, Yujin Guo, Zixin Li, Sheng Hu, Weidong Front Cell Dev Biol Cell and Developmental Biology Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we identified two genes (ANLN and ARNTL2) from multiple gene expression data sets, and developed a two-mRNA-based signature that can effectively distinguish high- and low-risk patients and predict patients’ response to immunotherapy. Furthermore, taking full advantage of the complementary value of clinical and molecular features, we combined the immune prognostic signature with clinical features to construct and validate a nomogram that can predict the probability of high tumor mutational burden (>10 mutations per megabyte). This may improve the estimation of immunotherapy response in LUAD patients, and provide a new perspective for clinical screening of immunotherapy beneficiaries. Frontiers Media S.A. 2021-01-26 /pmc/articles/PMC7875126/ /pubmed/33585490 http://dx.doi.org/10.3389/fcell.2021.634697 Text en Copyright © 2021 Song, Wu, Wang, Wang, Guo, Li and Hu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Song, Congkuan Wu, Zhiquan Wang, Qingwen Wang, Yujin Guo, Zixin Li, Sheng Hu, Weidong A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma |
title | A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma |
title_full | A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma |
title_fullStr | A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma |
title_full_unstemmed | A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma |
title_short | A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma |
title_sort | combined two-mrna signature associated with pd-l1 and tumor mutational burden for prognosis of lung adenocarcinoma |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875126/ https://www.ncbi.nlm.nih.gov/pubmed/33585490 http://dx.doi.org/10.3389/fcell.2021.634697 |
work_keys_str_mv | AT songcongkuan acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT wuzhiquan acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT wangqingwen acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT wangyujin acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT guozixin acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT lisheng acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT huweidong acombinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT songcongkuan combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT wuzhiquan combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT wangqingwen combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT wangyujin combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT guozixin combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT lisheng combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma AT huweidong combinedtwomrnasignatureassociatedwithpdl1andtumormutationalburdenforprognosisoflungadenocarcinoma |